Revolution Medicines (RVMD) Intangibles (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Intangibles of $55.8 million for Q1 2026, down 11.82% year-over-year from $63.3 million in Q1 2025, and little changed quarter-over-quarter from $55.8 million in Q4 2025.
Revolution Medicines (RVMD) Intangibles (2019 - 2026) Analysis & Trends
Revolution Medicines' Intangibles history runs 8 years deep, the most recent figure standing at $55.8 million for Q1 2026.
- In Q1 2026, Intangibles fell 11.82% year-over-year to $55.8 million; the TTM figure through Mar 2026 stood at $55.8 million (down 11.82% YoY), while the FY2025 annual figure was $55.8 million, down 1.54% from the prior year.
- Intangibles for Q1 2026 stood at $55.8 million, roughly flat from $55.8 million in the prior quarter.
- The five-year high for Intangibles was $63.3 million in Q1 2022, with the low at $55.8 million in Q1 2023.
- The 5-year median for Intangibles is $57.7 million (2023), against an average of $58.3 million.
- The sharpest annual moves came in 2023 and 2025: Intangibles dropped 11.82% in 2023, then rose 11.14% in 2025.
- Revolution Medicines' Intangibles stood at $58.8 million in 2022, then decreased by 1.82% to $57.7 million in 2023, then fell by 1.85% to $56.7 million in 2024, then decreased by 1.54% to $55.8 million in 2025, then changed by 0.0% to $55.8 million in 2026.
- Business Quant data shows RVMD's Intangibles at $55.8 million in Q1 2026, $55.8 million in Q4 2025, and $63.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.28 Mn |
| Mar 31, 2026 | 55.80 Mn |
| Dec 31, 2025 | 55.80 Mn |
| Sep 30, 2025 | 63.28 Mn |
| Jun 30, 2025 | 56.14 Mn |
| Mar 31, 2025 | 63.28 Mn |
| Dec 31, 2024 | 56.67 Mn |
| Sep 30, 2024 | 56.94 Mn |
| Jun 30, 2024 | 55.80 Mn |
| Mar 31, 2024 | 57.47 Mn |
| Dec 31, 2023 | 57.74 Mn |
| Sep 30, 2023 | 58.01 Mn |
| Jun 30, 2023 | 58.27 Mn |
| Mar 31, 2023 | 55.80 Mn |
| Dec 31, 2022 | 58.81 Mn |
| Sep 30, 2022 | 58.54 Mn |
| Jun 30, 2022 | 59.34 Mn |
| Mar 31, 2022 | 63.28 Mn |
| Dec 31, 2021 | 63.28 Mn |
| Sep 30, 2021 | 63.28 Mn |